Replies to post #1560 on Enanta Pharmaceuticals Inc (ENTA)

[10nisman]

I thought the magnitude of today's selloff was unwarranted given my view of ENTA’s prospects for the next couple of years and beyond.

What are your thoughts on the value of ENTA's Mavyret/HepC drugs? ENTA currently has approx $14/share in net cash leaving $30 left for everything else (HepC, Nash, etc.). Mavyret/HepC drugs are likely worth at least $30/share ($600 million) and everything else is free.